Pune-based entrepreneur's unlisted company is already the largest vaccine manufacturer in the world and the networth has been helped by vaccine distribution and manufacturing potential of his business, it added. Recentrly, Serum struck an agreement with AstraZeneca to manufacture 1 billion doses of coronavirus vaccine being developed by Oxford University.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
The hospital, located in Parel area, on Tuesday got the approval of the Maharashtra ethics committee for conducting the vaccine trials.
However, in two different dose regimens, the vaccine's efficacy was 90 per cent in one and 62 per cent in the other.
On Tuesday, Rao said there was a possibility of the PM's visit to Pune, and if that happens, it would be aimed at reviewing the status of the vaccine candidate for coronavirus infection and to know about its launch, production and distribution mechanisms.
British nationals arriving in India, irrespective of their vaccination status, will have to undergo 10 days of mandatory quarantine from October 4 as part of the reciprocal actions initiated by the government following the vaccine certification row between the two countries.
'Even if Serum Institute and Bharat Biotech were successful in ramping up production overnight, what happens to the capacity after the demand from India is met?' asks Sanjeev Nayyar.
This means there are now four promising vaccines on the horizon after Pfizer-BioNTech, Sputnik and Moderna already reporting good preliminary data from Phase 3 trials.
Ahmedabad was the first stop in the PM's three city tour today, to personally review the vaccine development and manufacturing process in the country.
Initial data has shown immunity triggered by the two mRNA vaccines -- Pfizer-BioNTech and Moderna -- lasts for at least six months
A Chennai-based man has demanded a compensation of Rs 5 crore from the SII after his health worsened allegedly after volunteering for the clinical trials for a COVID-19 vaccine.
Sputnik V is the third vaccine India has given the go-ahead to after 'Covishield', developed by Oxford University and AstraZeneca and 'Covaxin', the indigenous vaccine manufactured by Bharat Biotech. Covishield is manufactured by the Serum Institute of India.
Two male volunteers were administered the vaccine at Bharti Vidyapeeth's Medical College and Hospital, a senior office-bearer of the hospital said.
During the webinar, 'COVID-19: Vaccination and Potential Return to Normalcy - If and When', Dr Hotez, an internationally-recognised physician-scientist in neglected tropical diseases and vaccine development, said that the COVID-19 vaccine rollout is "India's gift' to the world in combating the virus.
The remarks come amid suspected cases of COVID-19 reinfection being reported from abroad and from Indian states like Telangana, Karnataka, Gujarat, Punjab and Maharashtra.
Amid reports of the ongoing coal shortage in the country, Finance Minister Nirmala Sitharaman stressed that there is no shortage and termed these as "absolutely baseless", saying India is a power surplus country. Sitharaman said that Power Minister R K Singh went on record just two days ago when he said absolutely baseless information is floating around that there is probably shortage of coal, shortage of other inventories which will lead to a sudden gap in the supply demand situation in the energy consumption. "Absolute baseless! There is no shortage of anything. In fact, if I recall the minister's statement, every power producing installation has the next four days' stock absolutely available within their own premises and the supply chain has not broken at all," Sitharaman said at Harvard Kennedy School on Tuesday.
Two men, aged 32 and 48, were given the first shot of the 'Covishield' vaccine, being manufactured by Pune-based Serum Institute of India, at Bharti Vidyapeeth's Medical College and Hospital on Wednesday. The dose will be repeated after one month, an official said.
Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time.
Ajit Mishra, vice president, research, Religare Broking, answers your stockmarket queries.
Launches cloud-based version of solution to target mid-size clients in life sciences.
The government may look at areas around Thonnakkal, in Thiruvananthapuram district, for the facility. If successful, this would be one of the few sites of Sputnik V owned by Russian firms outside that country. Shine Jacob and Sohini Das report.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of drugs - SGLT-2 inhibitors or gliflozins.
Not to say that India couldn't have handled the situation better, but on average, it didn't do anywhere near as badly as the naysayers make it out argues Rajeev Srinivasan.
Sensex eneded lower on poor perfromance by financials and IT stocks.
So far, no other vaccine has been approved globally for children below 12 years. Sohini Das reports.
Speaking during Prime Minister Narendra Modis video conference meeting with chief ministers of eight states which have reported high COVID-19 cases, Thackeray said the PM or Union Home Minister Amit Shah should convene a meeting of all parties to tell them about the seriousness of the situation.
Compared to their Indian peers, MNCs have higher return ratios.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Laws governing compensation in case of adverse side effects for Covaxin and Covishield may differ in accordance with the kind of approvals given, say legal experts.
Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India seeking emergency use authorisation for their COVID-19 vaccines.
'When there is so much anxiety, the Government of India should assure people on the vaccine issue and help the states demanding more supply that they will be provided the required quantities.' 'Any Centre-state conflict at this point of time is counter-productive and enhances people's anxieties that should be avoided.'
Responding to another question, Choubey said that the phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd, and now their immunogenicity testing is in progress. Their phase II clinical trials are ongoing.
'People are already sending congratulatory messages. But I have said, "Please don't until the trials are over".'
Investors cheered a sharp decline in the Current Account Deficit, which stands at a 4 year low as exports picked up and gold imports reduced.
'They are starting to move more quickly and we would just like to continue to see bold action being taken.'
'He came back from the US only to work for his country.' 'He has invested his fortunes to build this company and is married to his work.' 'Rarely does one see such commitment.'
There were apprehensions in the SII about rival Bharat Biotech's 'indigenous' tag, opening up shortcuts for it. One senior person, who was very familiar with the sector, told me, 'The message has gone out from the very top. Somani (V G Somani -- drug controller general of India) has told me "Bharat ka karna hai".' A fascinating excerpt from Abantika Ghosh's Billions Under Lockdown: The Inside Story Of India's Fight Against COVID-19.
Interacting with state chief ministers, Modi underscored the enormity of what he described as the world's biggest vaccination exercise, which begins from January 16, saying over 30 crore citizens will get the jabs in the next few months in India against only 2.5 crore people vaccinated so far in over 50 countries in around a month.
Scientists around the world, including in India, suggest it hasn't been tested properly given the time constraint and there may not be enough evidence to prove its efficacy.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances